Farallon Capital

Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
星期四, 五月 2, 2024
Research, General Health, Professional Services, Pharmaceutical, Infectious Diseases, Clinical Trials, Science, Biotechnology, Neurology, FDA, Finance, Health, Other Science, L.L.C, Longboard, Farallon Capital, Investment, Private, Food, FINANCIAL, Insurance, SAD, AAN, DSM-IV codes, Clinical trial, Medication, Food and Drug Administration

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.
  • In January 2024, Longboard raised $241.5 million in a follow-on public offering.
  • Longboard issued and sold 11,500,000 shares of common stock at a public offering price of $21.00 per share.
  • In March 2024, Longboard completed a Private Placement with an investment fund affiliated with Farallon Capital Management, L.L.C.

Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases

Retrieved on: 
星期四, 三月 21, 2024
Health, Infectious Diseases, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Farallon Capital, ARCH Venture Partners, Patient, Merck, Medicine, Investment, Therapy, OrbiMed, Machine learning, Probability, RTW, Pharmaceutical industry

Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.

Key Points: 
  • Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.
  • “At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy,” said Mark C. McKenna, chairman and CEO of Mirador.
  • To accelerate development, Mirador utilizes Mirador360, its proprietary precision development engine that leverages recent breakthroughs in human genetics and cutting-edge data science.
  • Mirador360 also allows Mirador to develop diagnostics and stratify heterogeneous patient populations for precise clinical development.

Zambia External Bondholder Steering Committee Reaches Agreement with Zambia on Debt Restructuring

Retrieved on: 
星期一, 三月 25, 2024
Index, Government, Documentation, Farallon Capital, Committee, LLP, RBC, IMF, AIP, Greylock Capital Management, OCC, The Committee, World Bank, Limited, Weil, Gotshal & Manges, Security (finance)

LONDON, March 25, 2024 /PRNewswire/ -- The Zambia External Bondholder Steering Committee (the "Committee") is pleased to announce that it has reached a conclusive agreement (the "2024 Agreement") with the Government of Zambia (the "Government") on a restructuring of Zambia's (i) US$750,000,000 5.375 per cent.

Key Points: 
  • LONDON, March 25, 2024 /PRNewswire/ -- The Zambia External Bondholder Steering Committee (the "Committee") is pleased to announce that it has reached a conclusive agreement (the "2024 Agreement") with the Government of Zambia (the "Government") on a restructuring of Zambia's (i) US$750,000,000 5.375 per cent.
  • Prompt implementation of a debt restructuring agreement with bondholders is not only in Zambia's interests, but the wider creditor community as a whole.
  • The proposed restructuring terms set out in the 2024 Agreement are based on the same structure as the November 2023 AIP.
  • Implementation of the 2024 Agreement is conditional on mutual agreement on deal documentation, and the objective is to fully implement the agreement as promptly as feasible.

Zambia External Bondholder Steering Committee Reaches Agreement with Zambia on Debt Restructuring

Retrieved on: 
星期一, 三月 25, 2024
Index, Government, Documentation, Farallon Capital, Committee, LLP, RBC, IMF, AIP, Greylock Capital Management, OCC, The Committee, World Bank, Limited, Weil, Gotshal & Manges, Security (finance)

LONDON, March 25, 2024 /PRNewswire/ -- The Zambia External Bondholder Steering Committee (the "Committee") is pleased to announce that it has reached a conclusive agreement (the "2024 Agreement") with the Government of Zambia (the "Government") on a restructuring of Zambia's (i) US$750,000,000 5.375 per cent.

Key Points: 
  • LONDON, March 25, 2024 /PRNewswire/ -- The Zambia External Bondholder Steering Committee (the "Committee") is pleased to announce that it has reached a conclusive agreement (the "2024 Agreement") with the Government of Zambia (the "Government") on a restructuring of Zambia's (i) US$750,000,000 5.375 per cent.
  • Prompt implementation of a debt restructuring agreement with bondholders is not only in Zambia's interests, but the wider creditor community as a whole.
  • The proposed restructuring terms set out in the 2024 Agreement are based on the same structure as the November 2023 AIP.
  • Implementation of the 2024 Agreement is conditional on mutual agreement on deal documentation, and the objective is to fully implement the agreement as promptly as feasible.

Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

Retrieved on: 
星期四, 三月 7, 2024
Citadel, SAN, Exchange, Sale, Inflammation, Security (finance), Farallon Capital

Gross proceeds of the private placement are expected to be approximately $100 million, before deducting placement agent fees and other expenses.

Key Points: 
  • Gross proceeds of the private placement are expected to be approximately $100 million, before deducting placement agent fees and other expenses.
  • The private placement is expected to close on March 11, 2024, subject to the satisfaction of customary closing conditions.
  • With the proceeds from the private placement, Ventyx expects to extend its cash runway into at least the second half of 2026.
  • Ventyx has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this private placement.

FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio

Retrieved on: 
星期五, 三月 1, 2024
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Therapy, Foresite Capital, GV, Artificial intelligence, Colorectal cancer, Record, Cancer, Growth, Johnson & Johnson, Helicon, MBA, Symbiosis, Data science, World Health Organization, Patient, MPH, Oncology, ARCH Venture Partners, Farallon Capital, Pharmaceutical industry

Alexis Borisy, an accomplished investor and entrepreneur, also joined the company's board of directors in the position designated to Nextech.

Key Points: 
  • Alexis Borisy, an accomplished investor and entrepreneur, also joined the company's board of directors in the position designated to Nextech.
  • The financing will fund the ongoing clinical development of FOG-001, the company’s first-in-class intracellular TCF-blocking β-catenin inhibitor currently being evaluated in a Phase 1/2 study in solid tumors.
  • The round will also accelerate the development of its robust portfolio of unique discovery programs, deepen its data science capabilities and strengthen its core Helicon therapeutics platform.
  • “Millions of colorectal cancer patients have been told by their oncologists that no more can be done for them.

Cliffwater Enhanced Lending Fund Adds Nicholas Lenicheck to Growing Platform

Retrieved on: 
星期一, 二月 12, 2024
DEL, Tudor Investment Corporation, Farallon Capital, Investment, Research, Bank

MARINA DEL REY, Calif., Feb. 12, 2024 /PRNewswire/ -- Cliffwater Enhanced Lending Fund ("CELFX" or "the Fund"), an interval fund providing access to alternative private debt strategies, announced Nicholas Lenicheck has joined its investment team as a Managing Director and will be based in New York.

Key Points: 
  • MARINA DEL REY, Calif., Feb. 12, 2024 /PRNewswire/ -- Cliffwater Enhanced Lending Fund ("CELFX" or "the Fund"), an interval fund providing access to alternative private debt strategies, announced Nicholas Lenicheck has joined its investment team as a Managing Director and will be based in New York.
  • Nick's extensive experience as an allocator to and direct investor in alternative credit investment strategies will support CELFX and its continued momentum.
  • Cliffwater, the investment adviser of CELFX, has been investing in enhanced lending since 2006.
  • The firm oversees over $7B in enhanced lending assets and over $37B in private debt assets.

AVROBIO and Tectonic Therapeutic Announce Merger

Retrieved on: 
星期二, 一月 30, 2024
Genetics, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Pulmonary hypertension, Hereditary hemorrhagic telangiectasia, Heart failure, Venture, Mergers and acquisitions, Patient, HHT, GPCR, Drug discovery, Concept, Biochemistry, Polaris Partners, Anemia, Harvard Medical School, Biophysics, Drug development, Disease, Bleeding, Fibrosis, Farallon Capital, Biology, G protein-coupled receptor, AVRO

AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”).

Key Points: 
  • AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”).
  • Under the terms of the agreement, AVROBIO will acquire 100% of the outstanding equity interests of Tectonic.
  • The private placement is expected to close in conjunction with the Merger in the second quarter of 2024.
  • “We are delighted to merge with AVROBIO at this important time for Tectonic.

Grosvenor's North American Property Business Announces Investment Team Leadership Changes

Retrieved on: 
星期四, 十二月 7, 2023
Colliers (company), Carbon, Acquisition, ICSC, SAN, Senior, Investment, Commercial Real Estate Women, Organization, Woman, American City Business Journals, CAD, Asset management, CREW, National Association, CIO, ULI, Shopping, Partnership, CBRE, Farallon Capital, Elementary, Urban Land Institute, Collier, BOMA, International Council, Management, Property management, Science

"Michael has been a foundational member of our executive team and a source of inspiration for people throughout our company," said Steve O'Connell, CEO of Grosvenor's North American urban property business.

Key Points: 
  • "Michael has been a foundational member of our executive team and a source of inspiration for people throughout our company," said Steve O'Connell, CEO of Grosvenor's North American urban property business.
  • "Michael has served as CIO for 12 of his 23 years with Grosvenor; he had overall responsibility for all of our Investment property transactions and oversaw our Asset Management team.
  • Michael's strong leadership within Grosvenor has left an enduring impact and he has set his team up for continued success."
  • Since 2011 he has overseen all Investment property transactions and the company's Investment portfolio across North America.

Zambia External Bondholder Steering Committee Statement regarding OCC stance on Comparability of Treatment

Retrieved on: 
星期一, 十一月 20, 2023
IMF, Common, Treatment, Government, Limited, Forgiveness, RBC, OCC, Government Gazette (Zambia), Appendix, Greylock Capital Management, AIP, MOU, LLP, International Monetary Fund, Committee, Comparability, Revise, Farallon Capital, Cryptocurrency, Bank

LONDON, Nov. 20, 2023 /PRNewswire/ -- The Zambia External Bondholder Steering Committee ("the Committee") is very disappointed and deeply concerned with recent developments with regard to implementing an agreement with the Government of Zambia (the "Government") on a restructuring of Zambia's (i) US$750,000,000 5.375 per cent.

Key Points: 
  • LONDON, Nov. 20, 2023 /PRNewswire/ -- The Zambia External Bondholder Steering Committee ("the Committee") is very disappointed and deeply concerned with recent developments with regard to implementing an agreement with the Government of Zambia (the "Government") on a restructuring of Zambia's (i) US$750,000,000 5.375 per cent.
  • Notably both Zambia and the Committee agreed that the AIP was compatible with the targets and parameters of the Debt Sustainability Analysis embedded in the approved International Monetary Fund ("IMF") program and the Comparability of Treatment principle as agreed with its Official Creditor Committee (the "OCC"), as confirmed in the Government's press statement of 26 October.
  • It is not for official bilateral creditors to dictate debt terms to other creditors in circumstances where the Government has confirmed Comparability of Treatment.
  • The Committee continues to stand ready and willing to implement the Revised AIP, supported by the Government and the IMF, if a way can be found to obtain OCC support or otherwise proceed with the debt restructuring Zambia so urgently needs.